GlobeNewswire Press

  1. Novotech Appoints Dr. Judith Ng-Cashin As Chief Medical Officer To Drive Global Medical Services 10/5/2023

    Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, announced today the appointment of Dr. Judith Ng-Cashin as Chief Medical Officer (CMO).

  2. CDMO Recro Announces The Addition Of Clinical-Scale Sachet And Blister Packaging Offerings 6/2/2021

    Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it has expanded the clinical capabilities of the company’s growing Clinical Trial Services (CTS) offerings.

  3. Karyopharm Donates 60,000 Medical Masks Across Massachusetts And The United States In Partnership With Family Reach, Myeloma Crowd And The Leukemia & Lymphoma Society 5/13/2020

    Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoing COVID-19 pandemic including cancer patients, their families, and the healthcare workers caring for them.

  4. Signals Analytics Powers Informa Pharma Intelligence's Offerings With Next Generation Advanced Analytics 4/22/2020

    Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and Signals Analytics, the next generation advanced analytics platform that leverages external data to uncover trends and novel insights, today announced a joint offering that helps life sciences companies to identify new opportunities, mitigate investment risks and accelerate the drug development process

  5. Itamar™ Medical Funds Clinical Study To Evaluate Potential Impact Of CPAP Therapy To Patients With COVID-19 4/22/2020

    Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices, solutions and a digital health platform to aid in the diagnosis of respiratory sleep disorders, today announced the initiation of a funded trial that will evaluate the use of CPAP to manage patients with confirmed or suspected COVID-19.

  6. Akcea And Ionis Report Positive Topline Phase 2 Study Results Of AKCEA-ANGPTL3-LRx 1/28/2020

    Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from the Phase 2 study of AKCEA-ANGPTL3-LRx in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).

  7. Parexel Unveils Combined Regulatory & Access Consulting Organization To Help Customers Optimize Delivery Of New Therapies To Patients 1/9/2020

    Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, today unveiled its fully-integrated Regulatory & Access consulting organization designed to optimize clinical development from the earliest stages.

  8. Foamix Announces Enrollment Of First Patient In Phase 2 Acne Clinical Trial For FCD105 Minocycline 3% And Adapalene 0.3% Combination Foam 9/19/2019

    Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), today announced that the first patient has been enrolled in its Phase 2 clinical trial to evaluate the efficacy and safety of its topical combination foam, comprised of minocycline 3% and adapalene 0.3%, FCD105 for the treatment of moderate-to-severe acne vulgaris.

  9. Interpace Enters Strategic Partnership Agreement With Genecast Biotechnology To Partner With Biopharma Solutions In China 9/16/2019

    Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that it has entered into a partnership agreement to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (“PRC”).

  10. Kura Oncology Doses First Patient In Phase 1 Clinical Trial Of Menin-MLL Inhibitor KO-539 In Acute Myeloid Leukemia 9/16/2019

    Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial of KO-539, the Company’s first-in-class inhibitor of the menin-mixed lineage leukemia (menin-MLL) interaction, in patients with relapsed or refractory acute myeloid leukemia (AML).